ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT)
Health Care · mRNA therapeutics and vaccines · NASDAQ
Arcturus Therapeutics develops self-amplifying mRNA therapeutics and vaccines, with the first approved sa-mRNA COVID vaccine (KOSTAIVE) generating revenue while advancing pipeline programs for rare genetic diseases.
What ARCTURUS THERAPEUTICS HOLDINGS INC does
Arcturus Therapeutics is a messenger RNA (mRNA) medicines company focused on developing therapeutics for liver and respiratory rare genetic diseases, as well as mRNA-based vaccines for infectious diseases. The company has proprietary platform technologies including STARR (self-amplifying mRNA) for immunogenic vaccines and LUNAR (lipid-mediated delivery system) for targeting RNA to disease-relevant tissues. Its internal pipeline includes candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), while its first approved product KOSTAIVE (sa-mRNA COVID-19 vaccine) is commercialized in Japan, the EU, and the UK through partnerships.
Themes: ["mRNA therapeutics","rare genetic diseases","mRNA vaccines","lipid nanoparticle delivery","respiratory diseases / cystic fibrosis","metabolic disorders / OTC deficiency"]
Fundamentals
- Price$7.16 as of 2026-07-09 close
- Market cap$195M as of 2026-07-10
- 1-year return-47.1% as of 2026-07-09 close
- Net margin-143.8% as of 2026-07-10
- ROE-36.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-61.9% as of 2026-07-10
- Revenue CAGR (3y)-26.4% SEC XBRL
- Beta2.26 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.